Nutra Pharma Corp., a biotechnology company that develops treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced yesterday that its drug discovery subsidiary ReceptoPharm published the positive results of its recent pain study in Toxicon, the official journal of the International Society on Toxinology. The study examined RPI-78, ReceptoPharm’s leading drug candidate for the treatment of pain, revealing that its pain reducing effects lasted four-times as long as morphine, without its associated negative side effects.

“The results from this study provide a significant step forward in the development of an effective and non-narcotic treatment for moderate to severe pain,” commented Dr. Paul Reid, CEO of ReceptoPharm. “With these results in hand, we believe that RPI-78 could become the first non opioid-based analgesic dedicated to treating Stage II and Stage III pain,” he added.

The ReceptoPharm study revealed that RPI-78 has a dose-dependent inhibitory effect on the electrical activity of Pf neurons in male rats. As per the study, RPI-78 lasted for at least 2 hours, compared to morphine, which lasted about 30 minutes. Molecularly, RPI-78 was observed to be 4,000 times more potent than morphine. Additionally, the study observed increased serotonin levels in subjects treated with RPI-78.

Rik J. Deitsch, Chairman and CEO of Nutra Phrarma Corp. stated, “While many opioid-based drugs provide fast and temporary pain relief, the negative side effect profiles and addictive properties of these medicines make them extremely difficult to administer. Because RPI-78 is more effective than morphine and does not produce these negative side effects, we believe that this drug could become the therapy of choice among hospitals and physicians in the near future.”